









Manuscript Doi: 10.1093/ecco-jcc/jjaa053 
© The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn’s 
and Colitis Organisation. All rights reserved. For permissions, please email: 
journals.permissions@oup.com 
The historical role and contemporary use of corticosteroids in 
inflammatory bowel disease 
Alexander M Dorrington1, Christian P Selinger2, Gareth C Parkes3, Melissa Smith4, Richard C Pollok5, 
Tim Raine1 
 
1 Cambridge University Hospitals Trust, Cambridge, UK 
2 Leeds Teaching Hospitals NHS Trust, Leeds, UK 
3 Royal London Hospital, Barts Health, London, UK 
4 Brighton and Sussex University Hospitals, Brighton, UK 
5 St George’s University Hospitals NHS Trust, UK 
 
Corresponding author:  
Dr Tim Raine 
Department of Medicine 
Addenbrooke’s Hospital 










/ecco-jcc/advance-article-abstract/doi/10.1093/ecco-jcc/jjaa053/5805149 by St G
eorge's U











Manuscript Doi: 10.1093/ecco-jcc/jjaa053 
 
ABSTRACT 
The use of corticosteroids to treat patients with inflammatory bowel disease (IBD) has been the 
bedrock of IBD therapeutics since the pioneering work of Truelove and Witts in the UK in the 1950s 
and subsequent large cohort studies in the US and Europe. Nevertheless, whilst effective for 
induction of remission, these agents do not maintain remission and are associated with a long list of 
recognised side effects, including a risk of increased mortality. With the arrival of an increasing 
number of therapies for patients with IBD, the question arises as to whether we are using these 
agents appropriately in contemporary practice. This review discusses the historical background to 
steroid usage in IBD, and also provides a brief review of the literature on side effects of 
corticosteroid treatment as relevant to IBD patients. Data on licensed medications is presented with 
specific reference to the achievement of corticosteroid-free remission. We review available 
international data on the incidence of corticosteroid exposure and excess and discuss some of the 
observations we and others have made concerning healthcare and patient-level factors associated 
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INTRODUCTION  
For over 70 years, corticosteroids have been a cornerstone therapy in the management of 
inflammatory bowel disease (IBD). Nevertheless, whilst effective for induction of remission, these 
agents do not maintain remission and are associated with a plethora of recognised adverse effects, 
including a risk of increased mortality. With the arrival of an increasing number of therapies for 
patients with IBD, the question arises as to whether these agents are being used appropriately in 
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Box text number 1: MECHANISM OF ACTION OF CORTICOSTEROIDS IN IBD 
 
Administered exogenous corticosteroids bind to the glucocorticoid receptor (GR), which is resident 
in the cytoplasm of all human cells. The activated GR complex can then migrate into the nucleus, 
where it regulates gene expression via direct binding of glucocorticoid responsive elements on DNA 
or by tethering itself to other transcription factors.1 In studies using triggered human mononuclear 
cells, corticosteroids powerfully reduce the production of the initial phase cytokines IL-1 beta and 
TNF-alpha, as well as of IL-6, IL-8 and GM-CSF. Synthesis of immunomodulatory cytokines such IL-2, 
IL-3, IL-4, IL-5, IL-10, IL-12 and IFN-gamma is similarly reduced.2  As a result, corticosteroids can exert 
a strong immunosuppressive effect, but this can come at the cost of undesirable and sometimes 
severe adverse effects, the range of which reflect the wide expression pattern of the GR and the 








Box text number 2: PHARMACOLOGICAL DIFFERENCES BETWEEN FIRST-GENERATION 
CORTICOSTEROIDS 
 
Given the heterogeneity in agents used in different IBD trials, a basic understanding of the different 
characteristics of commonly used systemic corticosteroids is important when reviewing the 
literature in this area. Table 1 summarises the key differences between available systemic 
corticosteroids. Hydrocortisone is a short-acting systemic corticosteroid with relatively high 
mineralocorticoid activity. In contrast, prednisone, prednisolone, and methylprednisolone are all 
intermediate-acting systemic corticosteroids that exert a stronger glucocorticoid effect in 
conjunction with diminished mineralocorticoid activity.3 Prednisone is a prodrug, which is converted 
to the active drug prednisolone in the liver. Therefore, both drugs are considered equivalent in 
terms of dose, glucocorticoid, and mineralocorticoid activity.4 Methylprednisolone has a slightly 
more potent glucocorticoid activity (4 mg is considered equivalent to 5 mg of 
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INDUCTION OF REMISSION 
After decades of poor outcomes and high mortality rates, the utility of corticosteroids in the 
treatment of IBD was first established in the 1950s. Several observational reports published between 
1950 and 1952 noted a subjective improvement in appetite and diarrhoea seen in ulcerative colitis 
(UC) patients who were given cortisone or ACTH.5–12 A breakthrough study in 1955 by Truelove and 
Witts published the findings of a multicentre randomised double-blind placebo-controlled trial 
examining 100 mg cortisone per day in a cohort of 210 patients with UC. After six weeks, 41·3% of 
patients treated with 25 mg cortisone four times per day were in remission, in comparison to 15·8% 
in the placebo arm (p < 0·001).13 In addition to the clinical outcomes, sigmoidoscopy carried out at 
the conclusion of the induction period was more likely to be normal in the cortisone treatment 
group (p = 0·02).13 Two subsequent controlled trials in the early 1960s found corticosteroids to be 
superior to sulphasalazine for inducing clinical remission in active UC.14,15 A 2011 meta-analysis of 
five randomised controlled trials concluded that corticosteroids are more effective than placebo for 
inducing remission in active UC (RR of no remission 0·65; 95% CI 0·45-0·93).16  
 
Truelove and colleagues also established the efficacy of systemic corticosteroids in acute 
severe UC in the 1970’s. In their landmark study, 87 patients received a complicated 
regimen of intravenous (IV) methylprednisolone 60 mg per day in four divided doses, in 
conjunction with a twice daily 100 mg hydrocortisone rectal drip in 120 ml normal saline for 
a total of five days. By day five, 60% of patients were free of symptoms, 15% had achieved a 
partial clinical response and 25% required colectomy.17,18 A 1985 uncontrolled Swedish 
study using IV betamethasone in place of methylprednisolone produced similar results, with 
56% of the 158 patients achieving clinical remission by day five. This group also showed that 
disease refractory to oral prednisolone could be treated intravenously.19 However, there 
does not appear to be any benefit in extending intravenous corticosteroid beyond seven to 
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reported an overall response rate to IV corticosteroids of 67%.21 In acute severe colitis, IV 
methylprednisolone may be preferred over hydrocortisone, as it has less mineralocorticoid 
activity, resulting in less hypokalaemia22 
 
High quality evidence supporting the use of corticosteroids in Crohn’s disease (CD) did not arrive for 
another two decades. In 1979, the National Cooperative Crohn’s Disease Study (NCCDS) published 
multicentre randomised controlled trial data from the United States demonstrating the superiority 
of prednisone (60%) over placebo (30%) in the induction of clinical remission in 295 patients with 
active CD.23 Moreover, the 1984 European Cooperative Crohn’s Disease Study (ECCDS) clearly 
demonstrated the superiority of methylprednisolone over placebo for achieving clinical remission at 
week six in a cohort of 215 patients with active CD.24 A 2008 Cochrane review including two placebo 
controlled trials and six 5-aminosalicylate (5-ASA) controlled trials confirmed the superiority of 
corticosteroids in achieving clinical remission over placebo (RR 1·99; 95% CI 1·51-2·64; p < 0·00001) 
and 5-ASA (RR 1·65; 95% CI 1·33-2·03; p < 0·00001) in CD.25 
 
Although systemic corticosteroid treatment improved short-term outcomes in UC and CD, side 
effects were becoming an increasingly recognised issue in clinical practice and the literature. Hence, 
the arrival of budesonide in 1994 as a treatment option in CD was timely. However, the unique 
pharmacokinetic properties of budesonide have restricted its use to patients with ileocolonic and 
right-sided colonic CD.26–28 A randomised controlled trial conducted in 186 patients with active ileal 
or ileocaecal CD found that 53% of patients treated with budesonide achieved clinical remission at 
week ten in comparison to 66% of patients who received prednisolone (p = 0·12). Prednisolone 
therapy did, however, achieve a greater reduction in disease activity than budesonide. Importantly, 
corticosteroid related side effects were less common in the budesonide group (p = 0·003).29 Several 
subsequent controlled studies confirmed the effectiveness of budesonide in achieving remission in 
active CD, with clinical remission rates at 8-12 weeks varying between 51 to 69%.30–34 A 2015 
Cochrane systematic review found that budesonide was superior to placebo in achieving remission 
in active CD, but was not as effective as conventional corticosteroids in the short term, particularly in 
those with severe disease and more extensive colonic involvement.35 
 
In the last two decades, second-generation corticosteroid preparations have also emerged for use in 
the management of UC. Two randomised placebo-controlled studies and a systematic review of ileal 
release budesonide have shown that it does not induce clinical remission in mild-moderate UC.36–38 
Budesonide MMX adopts a multi-matrix system that enables a targeted release of steroid within the 
colon.39 The CORE I and CORE II studies were randomised controlled trials comparing budesonide 
MMX 6 mg/day or 9 mg/day with placebo and Asacol 2·4 g/day (CORE I) or ileal release budesonide 
9 mg/day (CORE II) in mild-to-moderate UC.40,41 A pooled analysis of both trials showed a combined 
clinical and endoscopic remission rate of 17·7% for budesonide MMX 9 mg/day versus 6·2% for 
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powered to find differences between budesonide MMX and the active treatment arms.42 Subgroup 
analysis in CORE I and CORE II found that clinical and endoscopic remission was significantly better 
with budesonide MMX than placebo in left-sided disease, but not extensive disease.40,41 The lack of 
treatment benefit in extensive UC was confirmed in a subsequent Cochrane systematic review.38 A 
subsequent randomised controlled trial comparing budesonide MMX 9 mg/day with placebo in 510 
mild to moderate UC patients who were flaring on 5-ASA therapy, demonstrated a significant 
improvement in combined clinical and endoscopic remission (13% vs. 7·5%, p = 0·0488) and 
histological healing in the treatment arm (27% vs. 17·5%, p = 0·0155).43 
 
Beclomethasone dipropionate (BDP) is another second-generation corticosteroid that has evidence 
supporting its utility in UC. In a 2003 randomised controlled trial, BDP was shown to be as effective 
as 2·4 g 5-ASA in reducing the combined clinical and endoscopic disease activity index score in 177 
patients with active left-sided or extensive UC.44 In addition, the combination of BDP with 5-ASA was 
shown to be superior to 5-ASA alone in a similar patient cohort.45 A randomised double-blind study 
of 282 mild-to-moderate UC patients demonstrated that 5 mg BDP once daily was not inferior to 
tapered prednisone (starting at a dose of 40 mg once daily) in achieving the clinical response at week 
four (64·6% for BDP vs. 66·2% for prednisone [delta: −1·56; 95% CI −13·00–9·88, p = 0·78]).46 A 
subsequent systematic review of five controlled trials concluded that beclomethasone was superior 
to 5-ASA for achieving clinical improvement in mild-moderate UC (p = 0·003), with a trend toward a 
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MAINTENANCE OF REMISSION 
Although there is plentiful evidence demonstrating the efficacy of corticosteroids for inducing 
remission in IBD, data relating to the maintenance of remission is disappointing. In the landmark 
NCCDS study, among the 274 CD patients in clinical remission, prednisolone at doses of up to 20 mg 
per day did not reduce flares or disease recurrence after surgery.23 A 2003 Cochrane systematic 
review found that conventional oral corticosteroids do not reduce the risk of CD relapse over a 24-
month follow-up period.48 
 
A 2014 Cochrane systematic review that incorporated 1273 participants from 12 studies concluded 
that budesonide use beyond three months is ineffective at maintaining remission in CD.49 A 
subsequent systematic review and meta-analysis in 2018 also found that budesonide was no better 
than placebo in maintaining remission in CD.50 
 
The effectiveness of corticosteroids in achieving endoscopic mucosal healing and preventing 
endoscopic relapse in CD is also limited. In a French study of 136 CD patients who had achieved 
clinical remission after oral prednisolone 1 mg/kg/day for a duration of 3-7 weeks, 71% still had 
active endoscopic lesions. Only 13% of patients who were in clinical remission from corticosteroids 
had mucosal healing at endoscopy.51 Another study in 130 CD patients post-ileocaecal resection 
treated with either maintenance budesonide 6 mg/day or placebo found no difference in endoscopic 
recurrence in the neo-terminal ileum at 12 months (52% vs. 58% respectively).52  
 
Systemic corticosteroids are not effective for maintaining remission in UC. Truelove and Witts found 
that oral cortisone 50 mg/day was ineffective at maintaining remission in 68 UC patients who had 
initially achieved corticosteroid-induced clinical remission.53 Prednisone 15 mg/day (5 mg three 
times daily) was no different to placebo with regards to UC clinical relapse and remission after six 
months.54 With respect to mucosal healing in UC, an uncontrolled trial involving 157 patients treated 
with a 3 month tapered course of systemic corticosteroids within a year of initial diagnosis reported 
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SAFETY OF FIRST-GENERATION CORTICOSTEROID THERAPY 
Whilst corticosteroids have revolutionised the treatment of IBD since the mid-twentieth century, the 
widespread use of these agents has come at the cost of a myriad of adverse effects (AEs) for 
patients. Table 2 lists each of the AEs of corticosteroids with corresponding frequency based on 
published literature. It is worth noting that despite decades of use, there are still significant 
knowledge gaps in terms of the exact incidence of some AEs, particularly with regard to some of the 
less serious AEs that might nonetheless be of particular importance for patients. The frequency and 
severity of the overwhelming majority of AEs is dependent on the dose and duration of 
corticosteroids.56 In general, AEs are more likely to occur when corticosteroids are used daily for a 
period beyond two to three weeks.56 Approximately 50% of patients will develop short-term 
corticosteroid related AEs. Early side effects of corticosteroid therapy may include insomnia, acne, 
increased appetite, weight gain with cushingoid features, hypertension, hyperglycaemia, oedema, 
glaucoma, dyspepsia, mood disturbance, or psychosis.16 
 
Prolonged corticosteroid exposure can give rise to significant patient harm. In an active CD cohort, 
corticosteroid-related AEs at week 10 were reported in 55% of patients receiving prednisolone (40 
mg/day for two weeks with subsequent weaning) and in 33% of those on budesonide (9 mg/day for 
eight weeks, 6 mg/day for two weeks).29 A retrospective review of 30,456 United States veterans 
with IBD found that the risk of venous thromboembolism (VTE), fragility fracture, and infections per 
1000 person-years was higher in corticosteroid users versus non-users (9·0% vs. 4·9%, 2·6% vs. 1·9% 
and 54·3% vs. 26·9% respectively).57  
 
There is substantial evidence highlighting the increased risk of infection with systemic 
corticosteroids in IBD.57–60 A meta-analysis of 71 controlled corticosteroid trials found that dosages 
of prednisolone  20 mg/day double the risk of non-lethal and fatal infections.60 A study of 223 
patients with systemic lupus erythematosus (SLE) reported that the risk of infection rose from 1·5-
fold at a mean prednisolone dose below 10 mg/day to over 8-fold at doses above 40 mg/day.61 
Prospective registry cohorts in CD have demonstrated that the risk of serious infection is higher in 
patients being administered systemic corticosteroids.58,59 Additionally, a meta-analysis of 
observational studies concluded that corticosteroid use increased the risk of infectious 
postoperative complications in IBD patients undergoing surgery (OR 1·68 , 95% CI 1·24-2·28).62 
 
There is a multitude of evidence linking corticosteroid use with negative effects on bone density and 
growth. Corticosteroid exposure in the paediatric CD population is associated with growth failure 
and reduced adult height.63,64 Osteopenia and osteoporosis in IBD are common, with an estimated 
prevalence between 30 and 60%.65  Whilst the risk of these conditions in IBD is increased 
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UC and CD patients found the only significant predictor of diminished bone density at the hip and 
spine was corticosteroid use (p = 0·025).66 In a large UK retrospective cohort study including 244,235 
current oral corticosteroid users and the same number of matched controls, the relative risks of non-
vertebral fracture, hip fracture and vertebral fracture in the steroid users were 1·33 (95% CI 1·29-
1·38), 1·61 (95% CI 1·47-1·76) and 2·60 (95% CI 2·31-2·92) respectively. The degree of risk was 
demonstrated to be dose dependent. Relative to control, a daily dose of less than 2·5 mg of 
prednisolone had a vertebral fracture relative risk of 1·55 (95% CI 1·20-2·01), which rose to 2·59 
(95% CI 2·16-3·10) with daily doses of 2·5-7·5 mg, and further increased to 5·18 (95% CI 4·25-6·31) at 
daily doses above 7·5 mg. The same effect was seen with hip fracture risk. Upon cessation of 
corticosteroid treatment, a gradual reduction in fracture risk was observed over time, however the 
relative risk of fracture was still increased at 12 months after cessation of therapy.67 Whilst BMD 
improves after cessation of corticosteroids, it rarely recovers to pre-treatment levels.68  A meta-
analysis of 89 studies examining the relationship between corticosteroid use and bone mineral 
density (BMD) or fracture found that the risk of fracture increased sharply within the first three to 
six months of steroid treatment. It also concluded that doses of more than 5 mg prednisolone 
equivalent rapidly lead to a reduction in BMD and increased risk of fracture.69 A Cochrane systematic 
review of five trials found that calcium and vitamin D supplementation prevented bone loss from the 
forearm and lumbar spine in corticosteroid treated patients.70 Subsequently, multiple international 
guidelines advocate calcium and vitamin D supplementation in IBD patients receiving 
corticosteroids.71,72   
 
Compelling evidence has also emerged linking systemic corticosteroids to increased mortality in IBD. 
The TREAT registry provided prospective data on outcomes after a total of 30,963 patient-years of 
follow-up. Prednisone was found to increase mortality risk on multivariate analysis (HR 2·14, 95% CI 
= 1·55-2·95; p < 0·001), while other CD therapies, such as infliximab did not.59  In Europe, the 
ENCORE registry also prospectively followed up CD patients who received infliximab, conventional 
therapies, or a combination of both for five years. In this cohort, prednisone was the only agent 
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SAFETY OF SECOND-GENERATION CORTICOSTEROID THERAPY 
In comparison to traditional corticosteroids, budesonide tends to be better tolerated by patients, 
which is likely due to its high first-pass metabolism and limited systemic bioavailability.74 29,36 Short-
term use of methylprednisolone was found to suppress osteoblast activity, whilst budesonide did 
not.75 A randomised study of 272 patients with CD of the ileum and/or ascending colon given daily 
treatment with either budesonide or prednisolone for two years, found a milder degree of BMD loss 
in the budesonide group in those who were steroid naïve at entry (mean -1·04% vs -3·84%; p = 
0·0084).76 However, budesonide still appears to reduce bone mineral density. A two-year 
longitudinal study of 138 patients with quiescent CD found that those given budesonide 8·5 mg/day 
were more likely to develop more than 2% per annum BMD loss than a non-steroid group.77 
Although budesonide seems to cause some degree of adrenal suppression, morning cortisol levels 
remained in the normal range in two large studies including 899 patients.36,38 Clinically important 
corticosteroid-related side effects including sepsis, cataracts and adrenal insufficiency do not have a 
higher incidence in patients taking budesonide compared with placebo.78 
 
Budesonide MMX is well tolerated in UC patients. In a pooled analysis of three studies including over 
900 UC patients, budesonide MMX did not impair adrenocorticoid function, nor did it increase the 
risk of AEs over placebo.38 A recent review found that the safety profile of budesonide MMX and 
BDP was comparable to placebo when used for four to eight weeks in mild-to-moderate UC.79 
However, a randomised trial of 282 UC patients found that in comparison to prednisone, BDP use 
yielded no difference in steroid-related AEs and plasma cortisol less than 150 at week four (38·7% 
for BDP vs. 46·9% for prednisone [p = 0·17]).46 Conversely, a subsequent systematic review of five 
controlled trials – which included the previous study – concluded that BDP had a comparable safety 
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SYSTEMIC CORTICOSTEROID DOSAGE AND TAPERING 
There is heterogeneity in practice when it comes to dosing and tapering of systemic corticosteroids 
in IBD. The recommended oral corticosteroid doses for CD have been derived from the NCCDS, 
ECCDS and GETAID studies and have subsequently been extrapolated for use in UC.21–23,76 The NCCDS 
used oral prednisone at an initial dose of 0·5-0·75 mg/kg/day, which corresponded to treatment 
doses of 40-60 mg/day, whilst the ECCDS used methylprednisolone 48 mg daily (equivalent to 60 mg 
of prednisone) and GETAID used oral prednisolone 1 mg/kg/day. There have been no studies that 
directly compare oral prednisone and prednisolone in IBD.80 With respect to efficacy, the higher 
doses used in ECCDS and GETAID appeared to achieve better initial remission rates. Conversely, 
population data showed that remission rates using 40-60 mg/day in an Olmsted County CD cohort 
(58%) were superior to 1 mg/kg/day used in a Copenhagen cohort (48%) at 30 days.81,82 A single 
early study suggested that prednisone 40 mg/day was as effective as 60 mg/day in achieving clinical 
remission, whilst causing fewer side effects, which has led to many physicians preferring this starting 
dose. However, it should be noted that more patients in this study receiving the 40 mg starting dose 
did not improve or clinically worsened. Moreover, the additional side effects reported in the 60 mg 
starting dose group consisted of just two cases of facial mooning and one case of hypertension.83 As 
a result of these inconsistencies, current major guidelines have not recommended one dosing 
regimen over another.71,72,84 
 
The choice of corticosteroid tapering regimen used does not seem to alter outcome.85 Relapse rates 
in the NCCDS, ECCDS and GETAID trials were similar despite highly varied tapering protocols.23,24,86 A 
controlled CD study including 70 patients found that tapering intramuscular methylprednisolone 
over four weeks versus 12 weeks did not change rates of clinical remission induction or maintenance 
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TARGETS FOR CORTICOSTEROID THERAPY IN AN EVOLVING TREATMENT LANDSCAPE 
In light of the well-established toxicity of prolonged corticosteroid use, it is no surprise that major 
bodies have set targets and quality indicators specifically aimed at limiting patient corticosteroid 
exposure. The updated 2017 European Crohn’s and Colitis Organisation (ECCO) consensus guidelines 
on the diagnosis and management of UC emphasise that the overarching goal of maintenance 
therapy is to maintain steroid-free remission.88 The Crohn’s and Colitis Foundation of America (CCFA) 
stipulates that the percentage of patients taking prednisone (excluding those diagnosed in the last 
112 days) be used as a quality outcome measure for an IBD unit. The CCFA also uses the 
recommendation of steroid-sparing therapy after four months of corticosteroid therapy as a process 
quality indicator.89 The 2019 IBD Standards released by Crohn’s and Colitis UK advise that steroid 
treatment should be audited by individual IBD units on an ongoing basis.90 Patient representative 
bodies have also pinpointed steroid-free remission as a top priority for IBD patients.91  
 
Whilst corticosteroid-free remission has become an important outcome in modern IBD trials, the 
lack of uniformity and transparency in steroid dose and tapering protocols has meant that 
comparison of corticosteroid-free remission rates between studies is clouded by not only differences 
in study populations, but also varied steroid dosing and tapering rules. 92 Table 3 and Table 4 outline 
the differences in corticosteroid dosing and tapering rules between major randomised controlled 
trials in CD and UC respectively.  Bearing in mind that this heterogeneity prevents direct 
comparisons between trials, Table 5 and Table 6 summarise the key corticosteroid-free remission 
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CONTEMPORARY TRENDS IN CORTICOSTEROID USE 
Despite the introduction of effective IBD therapies, change in the application of corticosteroid 
therapy has been limited. A population-based study of 5300 IBD patients in Manitoba assessed 
trends in corticosteroid prescription based on the year of IBD diagnosis. Between diagnosis years 
1995 and 2004, there was no difference in the likelihood of a patient receiving corticosteroids over a 
five-year follow-up period (p = 0·152), despite the increasing use of immunomodulators in the 
cohort during that same period. In fact, over time between 1995 and 2008, patients were 
increasingly likely to receive corticosteroids within their first year of diagnosis (p = 0·025).93 In a 
population-based study of 1013 UC patients from South Korea diagnosed between 1986 and 2015 
that had a mean follow-up period of 108 months, 40.8%  of the cohort were exposed to systemic 
corticosteroids at least once, with the cumulative risk of exposure decreasing over time.94 Recent 
European prospective population-based inception cohort studies following patients diagnosed with 
CD (488 patients) and UC (717 patients) in 2010 found that 60% and 52% had been exposed to 
systemic corticosteroids after five years respectively. In addition, 14% of the UC cohort and 9% of 
the CD cohort had received steroids for greater than six consecutive months during the follow-up 
period.95,96 In the United States, a review of Veterans Health Administration data between 2002 and 
2010 revealed that of the 30,456 IBD patients included, 32% were exposed to corticosteroids, with 
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steroid prescription within a year were escalated to a corticosteroid-sparing medication. Review by a 
gastrointestinal specialist during a period of steroid use significantly increased the likelihood of 
commencement of corticosteroid-sparing therapy (68% vs. 31%, p < 0·001).57  
 
Chhaya and colleagues published UK data looking at corticosteroid prescribing trends between 1990 
and 2010 in 23,509 incident IBD cases. In CD, as thiopurine use increased, prolonged (> three 
months) oral corticosteroid exposure decreased over time (36·5% in 1990-1997 vs. 26·8% in 2002-
2010, p < 0·001). However, despite a similar increase in thiopurine use observed in UC, the use of 
oral corticosteroids within five years of diagnosis increased over time (29·9% in 1990-1993 vs. 48·5% 
in 2002-2005), as did rates of recurrent (15·3% in 1990-1993 vs. 17·8% in 2002-2005 [p = 0·02]) and 
very prolonged (> six months) exposure (11·0% in 1990-1997 vs. 13·0% in 2002-2010 [  = 0·03]).97 A 
Dutch study of similar methodology examining trends in 2,823 incident IBD cases between 1991 and 
2011 found that corticosteroid exposure within the first year of diagnosis was stable over time 
(54·0% in CD and 31·4% in UC). Cumulative corticosteroid exposure was observed to decline over 
time in CD, whilst in UC it initially decreased before plateauing. In CD, both immunomodulator and 
biological use were associated with a reduced risk of requiring corticosteroids (33·6% vs. 49·9%, p < 
0·01 and 25·7% vs. 38·2%, p = 0·04 respectively).98 A US retrospective observational study including 
1,119 IBD patients found that despite increased utilisation of biologic therapies for IBD between 
2003 and 2011, there was no significant reduction in corticosteroid prescription rates during the 
same time frame.99 Another recent study from the United States examined IBD treatment pathways 
between 2008 and 2016 for a large insured population consisting of 16,260 patients with CD and 
28,129 with UC. Alarmingly, corticosteroid monotherapy was the most common treatment pathway 
for CD (26%) and second most common pathway for UC (16%). 63% of these CD patients 
received two or more steroid cycles and 108 received ten or more cycles. There appeared to be an 
underutilisation of steroid-sparing strategies within the cohort. For example, biologic pathways were 
only used in 19% of CD patients and 6% with UC.100 
 
Fresh data suggests that health care providers underestimate corticosteroid use in IBD. A study 
survey of 812 patients and their treating physicians found that significantly more patients than 
medical practitioners reported corticosteroid use (25·9% vs. 20·8%, kappa = 0·735, p < 0·0001), and 
patients with routine follow-up were less likely to be treated with prolonged corticosteroid therapy 
(10·3% vs. 20·7%, p < 0·01).101 
 
A noteworthy limitation of these studies examining trends in corticosteroid use in IBD is their 
susceptibility to confounding by variables not reported or studied during the retrospective period of 
analysis. Our group published a prospective multi-centre audit of excess steroid use in IBD in the 
United Kingdom. In this study, steroid dependency or excess was defined in accordance with ECCO 
and UK guidelines.71,102,103 For cases with steroid dependency or excess, anonymised records were 
submitted for blinded peer review and in cases where efforts to avoid steroid dependency or excess 
were judged suboptimal or absent, a finding of inappropriate steroid excess was recorded. Of the 
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excess. 49·1% of these patients were judged to have inappropriate steroid dependency or excess, 
with an annual incidence of inappropriate steroid excess of 7·1%. Inappropriate steroid therapy was 
associated with a number of patient and service-level factors. Treatment at a centre with dedicated 
IBD clinics was a protective factor in UC (OR = 0·64, 95% CI 0·21-0·94), whilst having an established 
IBD multidisciplinary team was protective in CD (OR = 0·62, 95% CI 0·46-0·91). Patients with CD who 
were treated with 5-ASA therapy were more likely to experience steroid dependency or excess (OR 
1·87 [CI 1·01-3·91]), highlighting this measure as a potential surrogate marker of quality of care. We 
also analysed the source of steroid prescription in patients identified as having corticosteroid 
dependency or excess. In 17·0% of cases, the decision to commence steroid was made in primary 
care. 91·3% of these cases were classed as avoidable corticosteroid excess, versus 42·0% of cases 
initiated in secondary care (p < 0·0001).104 
 
We performed a follow-up study in 2017 including 2,385 patients across 19 UK centres, and found a 
very similar overall rate of steroid excess or dependency (14.8%). Again, roughly half of this excess 
(50.7%) was deemed to be avoidable. Seven of the centres included in the 2015 study had 
subsequently undertaken a quality improvement programme focused on reducing steroid excess. In 
the follow-up period, these intervention centres achieved lower corticosteroid exposure (23·8% vs. 
31·0%, p < 0·001) and excess (11·5% vs. 17·1%, p < 0·001). Importantly, this effect remained even 
after we corrected for other characteristics in a multivariate analysis.105   
 
STRATEGIES TO COMBAT CORTICOSTEROID EXCESS 
There appear to be multiple underlying reasons for the high prevalence of corticosteroid use in 
contemporary IBD care. Unfortunately, few steroid-sparing agents exist that can induce a swift 
clinical response during an IBD flare and corticosteroids undeniably still play a key role in this setting. 
In addition, there are often logistical and financial barriers for rapid access to some steroid-sparing 
therapies, as well as a lack of awareness of steroid-sparing options, particularly in primary care.106 
Practical solutions to combat corticosteroid excess in IBD are vital in order to prevent avoidable 
short and long-term toxicity.  
 
PRIMARY CARE 
A significant proportion of steroid prescribing for IBD in primary care is inappropriate.104 Engaging 
with and educating patients and general practitioners (GPs) with respect to the limitations and 
consequences of corticosteroid therapy in IBD may reduce the likelihood of inappropriate 
corticosteroid prescriptions in this setting. When surveyed in 2017, half of GPs in the UK said they 
lacked confidence in managing IBD and two thirds requested further education. In response, the 
Royal College of General Practitioners (RCGP) created an IBD online toolkit and electronic learning 
resource specifically for primary care providers.106 Equipping GPs with better knowledge regarding 5-
ASA optimisation principles in UC could reduce unnecessary corticosteroid exposure, as may 
empowering UC patients with 5-ASA self-management strategies in the response to a disease flare. 
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steroid-sparing options along with improved access for patients to secondary care. IBD telephone 




The introduction of a local quality improvement programme focused on combating avoidable steroid 
use can result in a rapid decline in rates of excess exposure.105 Rapid and efficient assessment, 
investigation and management of suspected new IBD cases and flares in secondary care is crucial in 
order to commence corticosteroid-sparing treatments in a timely fashion. Therefore, service 
pathways enabling prompt review of symptomatic outpatients with, or suspected of having IBD are 
important to have in place. Similar pathways should also be in place for patients with newly 
diagnosed IBD at endoscopy. Clinicians should be educated to escalate IBD therapy promptly when a 
current strategy is not adequately controlling the disease. Real world UC studies have suggested that 
oral steroid failure rates in moderate flares appear to be similar to those with intravenous steroids in 
severe flares. Thus, timely assessment of response to corticosteroid therapy is important to enable 
early detection of non-responders and facilitate prompt treatment escalation.55,107 Dedicated IBD 
clinics appear to be superior to general gastroenterology clinics in reducing inappropriate 
corticosteroid excess.104 Regular IBD multidisciplinary team meetings to discuss complex cases have 
also been shown to reduce the risk of inappropriate steroid excess.104,105 Moreover, the use of a 
multidisciplinary team to explore steroid-sparing options in patients on prolonged corticosteroid 
therapy is recommended by the new British Society of Gastroenterology (BSG) IBD consensus 
guidelines.72 
 
In order to self-assess steroid prescribing practices, IBD units should undertake steroid auditing on a 
regular and continued basis. Auditing of steroid use within an IBD unit can result in a reduction in 
inappropriate corticosteroid prescribing.108 Analogous to the use of caecal intubation rate in 
colonoscopy quality control, rates of corticosteroid prescribing in an IBD service could be 
benchmarked and monitored. For this reason, auditing of corticosteroid rates within an IBD service 
has been recommended by the 2019 UK IBD Standards.90 At this point, key performance indicator 
targets for corticosteroid prescription are not clear, however major variation in prescription rates 
between centres should be a trigger to analyse the underlying factors responsible and address 
reversible causes. 
 
In the future, there may be a role for novel steroid-sparing strategies, such as small molecule burst 
therapy for the management of IBD flares, however evidence supporting the safety and efficacy of 
such a strategy is lacking at this time. If corticosteroid therapy is genuinely required, clinicians should 
always consider whether second-generation corticosteroid agents may be appropriate in an effort to 
minimise AEs. For instance, a UK population-based study reported a potential underutilisation of 
ileal release budesonide in CD. Between 1990 and 2009, 50·7% of CD patients received 
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There is little argument that corticosteroids have revolutionised the treatment of IBD, particularly 
given their unparalleled effectiveness for inducing remission in the short-term. These agents are, 
however, ineffective in the maintenance of IBD and cause substantial harm to patients, particularly 
with prolonged use. Despite the emergence of multiple new corticosteroid-sparing IBD therapies 
over the last two decades, the rate of steroid use has not significantly declined and much of the 
exposure appears to be avoidable. Local implementation of strategies targeting corticosteroid excess 
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TABLES 
Table 1: Pharmacologic comparison of commonly used systemic glucocorticoids.3 
 Equivalent dose 
(mg) 
Glucocorticoid activity 
relative to hydrocortisone 
Mineralocorticoid activity 
relative to hydrocortisone 
Duration of 
action (hours) 
Short acting     
Hydrocortisone 20 1 1 8 - 12 
Cortisone acetate 25 0.8 0.8 8 - 12 
Intermediate acting     
Prednisone 5 4 0.8 12 - 36 
Prednisolone 5 4 0.8 12 - 36 
Methylprednisolone 4 5 0.5 12 - 36 
Triamcinolone 4 5 0 12 - 36 
Long acting     
Dexamethasone 0.75 30 0 36 - 72 
Betamethasone 0.6 30 0 36 - 72 
Mineralocorticoids     
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Table 2: Adverse effects of first-generation corticosteroids with reported frequencies based on 
published evidence. 





   
 Skin thinning 10% After > 6 months exposure110  
 
 Ecchymoses / purpura 17% After > 6 months exposure110  
 
 Acne ·· No data available 
 Striae ·· No data available 
 Hirsutism ·· No data available 
 Cushingoid appearance 24·6% at > 7·5 mg /day 
 
After > 6 months exposure110  
  15·8% at 5 – 7·5 mg / day 
 
After > 6 months exposure110 
  4·3% at < 5 mg / day After > 6 months exposure110 
 Weight gain 70% Self-reported from a group exposed to a mean 
prednisone dose of 16 mg / day for > 60 days111 
  22·3 %  After > 6 months exposure to at least 5 mg per 
day110  
Ophthalmic    
 Cataracts 29% In rheumatoid arthritis (RA) population taking 
mean prednisone dose of 8 mg / day for an 
average of 6·7 years112 
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of 6 mg / day for an average of 6 years113  
 Glaucoma ·· More common with topical ocular steroids than 
systemic therapy114 
Cardiovascular    
 Hypertension 84·7% (vs 67·3% in control [p = 
0·028]) 
In RA patients treated with prednisolone 7·5 – 
30 mg / day for > 6 months115 
  HR 1·2 (95% CI 1·1-1·4 [p = 
0·004]) 
In RA patients exposed to a mean 8·1 mg / day 
dose of prednisone116 
 Venous thromboembolism OR 2·2 (95% CI 1·7-2·9) Meta-analysis of 8 observational studies 
including 58,518 IBD patients117 
 Oedema ·· No data available 
 
Gastrointestinal    
 Peptic ulcer disease RR 2·3 (95% CI 1·4-3·7) 
 
RR 1·1 (95% CI 0·5-2·1) 
Pooled data from 71 controlled trials118  
 
Nested case control study119  
 Gastrointestinal 
haemorrhage 
RR 1·5 (95% CI 1·1-2·2) Pooled data from 71 controlled trials118 
 
Musculoskeletal    
 Osteoporosis / fracture 30-50% Incidence of fracture when exposed to chronic 
corticosteroid therapy120  
Incidence increases with larger dose and longer 
duration111,121 
 Osteonecrosis 0·13% Incidence of avascular necrosis amongst 98, 390 
patients treated with a low dose 
methylprednisolone taper122 .  Risk increases 
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 Growth failure ·· Corticosteroid use in paediatric CD results in 
reduced adult height63 
 Myopathy ·· No data available 
 
Neuropsychiatric    
 Sleep disturbance ·· Usually worse with evening or split dosing 
  
 Mood disorder 60% In a small cohort receiving prednisone 7·5 mg 
per day for 6 months126  
 
 Psychosis ·· Typically only seen at doses > 20 mg prednisone 
per day127,128 
 
Endocrine    
 Hypothalamic-pituitary-
adrenal axis suppression 
·· Does not occur at a < 5mg morning prednisone 
dose equivalent or with corticosteroid therapy 
at any dose for a duration < 3 weeks129–131 
 Hyperglycaemia  RR of requiring hypoglycaemic 
therapy 2·23 (95% CI 1·92–2·59) 
Case-control study including 11, 855 cases with 
newly initiated hypoglycaemic therapy with the 
same number of controls; dose-dependent 
effect132 
 
Immune    
 Impaired wound healing ·· No data available 
 Serious infection HR 1·57 (95% CI 1·17-2·10) TREAT registry data59  
General    
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Table 3: Corticosteroid dose and tapering regimens from major randomised control trials in 
moderate-severe Crohn’s disease.92 
 Patient numbers 






















I: 37 (Adalimumab) 
P: 56 
I: 46 
30mg/day Week 8 Week 16 Reduce by 5mg/week 
until 10mg/day then 
2.5mg/week 
CHARM134 P: 170 
I: 329 (Adalimumab) 
P + I: 42 30mg/day Week 8 Week 16 Reduce by 5mg/week 
until 10mg/day then 
2.5mg/week 
GEMINI II135 P: 153 
I: 308 (Vedolizumab) 
P: 54 
I: 53 
30mg/day Week 6 Week 14 Reduce by 5mg/week 
until 10mg/day then 
2.5mg/week 





40mg/day Week 8 Week 18 Reduce by 5mg/week 
until 10mg/day then 
2.5mg/week 
* A uniform corticosteroid taper was not enforced. In the event of clinical worsening, investigators 
were permitted to increase the dose back up to the corticosteroid dose at trial entry and then 
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Table 4: Corticosteroid dose and tapering regimens from major randomised controlled trials in 
moderate-severe ulcerative colitis.92 
 Patient 
numbers 






















40mg/day Week 8 Week 20 Reduce by 5mg/week until 
20mg/day then 2.5mg/week 





40mg/day Week 8 Week 20 Reduce by 5mg/week until 
20mg/day then 2.5mg/week 





20mg/day Week 8 Week 14 Reduce by 5mg/week until 
10mg/day then 2.5mg/week 





40mg/day Week 6 Week 18 Reduce by 5mg/week until 
20mg/day then 2.5mg/week 





30mg/day Week 6 Week 14 Reduce by 5mg/week until 








25mg/day Week 5 Week 14 Reduce by 5mg/week until 
20mg/day then 2.5mg/week 
* A uniform corticosteroid taper was not enforced. In the event of clinical worsening, investigators 
were permitted to increase the dose back up to the corticosteroid dose at trial entry and then 
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Table 5: Summary of trial data publishing corticosteroid-free remission data for different 
















15 mg weekly 
RCT Total: 76  
Methotrexate: 40 
Placebo: 36 
40 weeks Methotrexate: 
72% 
Placebo: 42% 
P = 0.01 
Chande et 
al143  











dose < 10mg per 
day) 
RR: 1.34 
(95% CI 1.02 – 
1.77) 
SONIC144 2010 Arm 1: 
Azathioprine 




RCT Total: 508 
Arm 1: 170 
Arm 2: 169 
Arm 3: 169 








P = 0.006 for 
infliximab vs 
azathioprine 




CHARM134 2007 Adalimumab RCT Total: 778 
Adalimumab 40 mg 
second weekly: 260 
Adalimumab 40 mg 
weekly: 257 
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Placebo: 261 Placebo: 3% 
GEMINI 
II135 
2013 Vedolizumab RCT Total: 461 
Vedolizumab 8 weekly: 
154 
Vedolizumab 4 weekly: 
154 
Placebo: 153 





P = 0.02 for 8 
weekly vs 
placebo 





2016 Ustekinumab RCT Total: 388  
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Table 6: Summary of trial data publishing corticosteroid-free remission data for different 
maintenance treatments in ulcerative colitis 
Author / Trial 
name 









2006 Azathioprine  RCT Total: 72 
Azathioprine 2 
mg/kg/day: 36 
Oral 5-ASA 3.2 g/day: 
36 
 
26 weeks Azathioprine: 53% 





(95% CI 1.57 
– 14.5) 
ACT 2137 2005 Infliximab RCT Total: 364 
Infliximab 5 mg/kg: 121 
Infliximab 10 mg/kg: 
120 
Placebo: 123 
30 weeks Infliximab 5 mg/kg: 
18.3% 
Infliximab 10 mg/kg: 
27.3% 
Placebo: 3.3% 
P = 0·01 for 
5 mg/kg 
P < 0·001 for 
10 mg/kg 










ULTRA 2138 2013 Adalimumab RCT Total: 494 
Adalimumab: 248 
Placebo: 246 
52 weeks Adalimumab: 13.3% 
Placebo: 5.7% 
P = 0.035 
PURSUIT-
Maintenance139 
2014 Golimumab RCT Total: 464 
Golimumab 50 mg: 154 
Golimumab 100mg: 154 
Placebo: 156 
52 weeks Golimumab 50 mg: 
28.2% 
Golimumab 100 mg: 
23.2% 
P = 0.279 for 
50 mg vs 
placebo 
P = 0.423 for 
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Placebo: 18.4% placebo 
 
GEMINI I140 2013 Vedolizumab RCT Vedolizumab 4 weekly: 
125  









P < 0.001 for 
4 weekly vs 
placebo 
P = 0.01 for 
8 weekly vs 
placebo 
VARSITY147 2019 Adalimumab 
vs 
Vedolizumab  
RCT Total: 769  
Adalimumab: 
Vedolizumab: 





18.9 – 0.4) 
OCTAVE 
Sustain141 
2017 Tofacitinib RCT Total: 593 
Tofacitinib 5 mg twice 
daily: 198 
Tofacitinib 10 mg twice 
daily: 197 
Placebo: 198 
52 weeks Tofacitinib 5 mg twice 
daily: 35.4% 
Tofacitinib 10 mg 
twice daily: 47.3% 
Placebo: 5.1% 
P < 0.001 for 
both doses 
UNIFI148 2019 Ustekinumab RCT Total: 523 










P < 0.001 for 
8 weekly vs 
placebo 
P = 0.002 for 
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